巨噬细胞糖酵解在脓毒症中的研究进展

AThe research progress of macrophage glycolysis in sepsis

脓毒症是由感染引起的一种异质性综合征,免疫功能紊乱是其重要的病理机制。巨噬细胞介导的免疫反应贯穿于脓毒症的整个发展过程,糖酵解增强是脓毒症时巨噬细胞重要的代谢方式,通过促进巨噬细胞的炎症反应并影响其表型,进一步促进脓毒症发展,而直接或者间接抑制巨噬细胞的糖酵解则可减轻脓毒症及其所致的器官功能损害并促进抗炎表型极化。本文综述了巨噬细胞糖酵解与脓毒症的关系,以及调节巨噬细胞糖酵解途径以调控脓毒症的相关分子机制。通过调节巨噬细胞糖酵解,可能为脓毒症提供新的治疗策略。

Sepsis is a heterogeneous syndrome.It is caused by infections,attributing to immune dysfunction pathologically.The disease is characterized by macrophage-mediated inflammation and immune response throughout its development.During septic development,macrophages metabolize crucially with glycolysis remarkably enhanced.The glycolystic enhancement facilitates septic development by promoting the inflammatory response of macrophages and altering their phenotype.Therefore,direct or indirect inhibition of macrophagic glycolysis can alleviate sepsis and neutralize damages to organs functionally,promoting the polarization of anti-inflammatory phenotype.In this review,we aim to investigate the relationship between macrophagic glycolysis and sepsis,focusing on researching into relevant molecular mechanisms by which glycolysis is regulated for treating sepsis.It is concluded that interfer‐ing with macrophagic glycolysis may serve as a novel therapeutic strategy for treating sepsis.